Belvedere Trading
NVO

Belvedere Trading’s Novo Nordisk NVO Stock Holding History

Belvedere Trading’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47,500
Closed -$2.42M – 932
2025
Q4 		$2.42M Buy
+47,500
New +$2.43M ﹤0.01% 119
2023
Q1 		– Sell
-7,000
Closed -$474K – 1291
2022
Q4 		$474K Buy
+7,000
New +$410K ﹤0.01% 140

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Belvedere Trading's NVO Position: Q1 2026 in Review

Belvedere Trading increased its Novo Nordisk (NVO) stake by 75% in Q1 2026, buying an estimated $88.1K and bringing the position to 4,326 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #465.

Belvedere Trading first reported a position in NVO in Q4 2025 and has held it in 2 quarters since. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Belvedere Trading held 4,326 shares of Novo Nordisk worth $159K as of Q1 2026.
  • Belvedere Trading bought 1,860 Novo Nordisk shares in Q1 2026, an estimated $88.1K.
  • Novo Nordisk made up ﹤0.01% of Belvedere Trading's portfolio in Q1 2026, its #465 holding.
  • Belvedere Trading first reported a position in Novo Nordisk in Q4 2025 and has held it in 2 quarters since.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.